The FDA granted accelerated approval to Johnson & Johnson’s Rybrevant Faspro for advanced head and neck cancer that has returned after prior chemotherapy and immunotherapy. The approval extends the bispecific antibody’s label beyond its earlier lung cancer indication. The accelerated pathway signals a reliance on surrogate endpoints while confirmatory evidence is expected through additional studies. For oncology strategists, the label expansion adds a new treatment option in a hard-to-treat population with limited post–standard-therapy choices. The report frames the decision as a fast-moving regulatory step, positioning Rybrevant Faspro for broader uptake among eligible patients.